kaonavi
4435
Wintest
6721
Itamiarts
168A
Allied Telesis Holdings KK
6835
D. Western Therapeutics Institute
4576
(Q1)Dec 31, 2024 | (FY)Sep 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 131.80%7.32B | -8.08%19.17B | -58.69%4.09B | 1.81%3.16B | 0.70%20.85B | 4.86B | -42.39%2.99B | 156.03%9.9B | -39.27%3.1B | 36.58%20.71B |
Cost of revenue | 102.64%2.4B | 4.39%6.86B | -19.38%1.67B | -19.08%1.18B | -7.09%6.57B | 1.75B | -20.51%1.29B | 45.21%2.07B | -15.51%1.46B | 31.22%7.07B |
Gross profit | 149.31%4.92B | -13.82%12.31B | -69.05%2.42B | 20.49%1.97B | 4.74%14.28B | 3.11B | -52.39%1.69B | 220.54%7.84B | -51.47%1.64B | 39.53%13.63B |
Operating expense | 13.86%1.57B | -13.16%5.93B | -49.85%1.35B | 5.65%1.38B | 74.23%6.83B | 1.48B | 25.47%1.35B | 259.55%2.69B | 63.07%1.31B | 22.56%3.92B |
Operating profit | 465.11%3.35B | -14.42%6.38B | -79.12%1.07B | 79.16%591.95M | -23.30%7.45B | 1.64B | -86.20%342.39M | 203.30%5.14B | -87.15%330.41M | 47.79%9.71B |
Net non-operating interest income (expenses) | 0.10%1M | 164.16%3.97M | 9.03%169K | -0.20%1M | 27.13%1.5M | 337K | 0.00%7K | 27.05%155K | 9.60%1.01M | 18.66%1.18M |
Non-operating interest income | 8.47%1.09M | 165.96%4M | 9.03%169K | -0.20%1M | 18.80%1.5M | --337K | 0.00%7K | 27.05%155K | 0.50%1.01M | 26.98%1.27M |
Non-operating interest expense | --84K | --27K | ---- | ---- | --0 | --0 | ---- | ---- | ---- | --83K |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 125,695.31%160.76M | 2,168.03%88.31M | 98.33%-71K | -326.67%-128K | 50.58%-4.27M | 0 | 0 | -4.24M | 99.65%-30K | -200.24%-8.64M |
Less:Other special charges | -125,695.31%-160.76M | -2,168.03%-88.31M | -98.33%71K | 326.67%128K | -50.58%4.27M | --0 | --0 | --4.24M | -99.65%30K | 200.24%8.64M |
Other non-operating income (expenses) | -100.32%-266K | -92.32%1.84M | -22.94%5.02M | 18,650.77%84.41M | -60.52%23.93M | 13.63M | -78.40%4.24M | -78.58%6.51M | -104.55%-455K | 238.77%60.63M |
Income before tax | 417.80%3.51B | -13.41%6.47B | -79.03%1.08B | 104.64%677.24M | -23.50%7.47B | 1.65B | -86.13%346.64M | 198.07%5.14B | -87.14%330.93M | 48.24%9.77B |
Income tax | 343.82%1.18B | -38.22%2B | -82.66%376.48M | 6.63%266.13M | 9.21%3.24B | 621.45M | -74.19%202.89M | 268.50%2.17B | -69.66%249.58M | 30.54%2.97B |
Net income | 465.69%2.33B | 5.65%4.46B | -76.38%702.09M | 405.31%411.1M | -37.81%4.23B | 1.03B | -91.61%143.76M | 161.56%2.97B | -95.35%81.36M | 57.59%6.79B |
Net income continuous operations | 465.69%2.33B | 5.65%4.46B | -76.38%702.09M | 405.31%411.1M | -37.81%4.23B | --1.03B | -91.61%143.76M | 161.56%2.97B | -95.35%81.36M | 57.59%6.79B |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 465.69%2.33B | 5.65%4.46B | -76.38%702.09M | 405.31%411.1M | -37.81%4.23B | 1.03B | -91.61%143.76M | 161.56%2.97B | -95.35%81.36M | 57.59%6.79B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 465.69%2.33B | 5.65%4.46B | -76.38%702.09M | 405.31%411.1M | -37.81%4.23B | 1.03B | -91.61%143.76M | 161.56%2.97B | -95.35%81.36M | 57.59%6.79B |
Gross dividend payment | ||||||||||
Basic earnings per share | 465.92%73.23 | 5.56%140.58 | -76.40%22.11 | 405.47%12.94 | -37.83%133.17 | 32.39 | -91.61%4.53 | 161.41%93.69 | -95.36%2.56 | 56.76%214.21 |
Diluted earnings per share | 465.44%72.15 | 6.32%138.64 | -76.19%21.79 | 408.37%12.76 | -37.59%130.4 | 31.81 | -91.42%4.53 | 162.06%91.51 | -95.32%2.51 | 57.98%208.93 |
Dividend per share | 0 | 0.00%40 | 0 | 0 | 40 | 40 | ||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |